Deciphera Pharmaceuticals Logo in transparent PNG format

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 in combination with RTK/RAS/MAP kinase signaling pathway inhibition to treat RAS/RAF mutant cancers. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.